CD276 and cancer: Recent studies have demonstrated that some inhibitory B7 family ligands, such as B7-H1, B7-DC, B7-H3 and B7-H4, are highly expressed in a wide spectrum of human cancers, and their expression levels are correlated with patients' clinicopathological features.